Ipnobioma: una nuova frontiera dell’ipnositerapia? Uno studio pilota e una revisione della letteratura

Titolo Rivista IPNOSI
Autori/Curatori Giuseppe De Benedittis
Anno di pubblicazione 2022 Fascicolo 2021/2
Lingua Italiano Numero pagine 21 P. 5-25 Dimensione file 304 KB
DOI 10.3280/IPN2021-002001
Il DOI è il codice a barre della proprietà intellettuale: per saperne di più clicca qui

Qui sotto puoi vedere in anteprima la prima pagina di questo articolo.

Se questo articolo ti interessa, lo puoi acquistare (e scaricare in formato pdf) seguendo le facili indicazioni per acquistare il download credit. Acquista Download Credits per scaricare questo Articolo in formato PDF

Anteprima articolo

FrancoAngeli è membro della Publishers International Linking Association, Inc (PILA)associazione indipendente e non profit per facilitare (attraverso i servizi tecnologici implementati da CrossRef.org) l’accesso degli studiosi ai contenuti digitali nelle pubblicazioni professionali e scientifiche

Una crescente evidenza suggerisce che l’asse intestino-cervello possa svolgere un ruolo chiave nelle condizioni di salute e malattia attraverso una rete di comuni-cazioni bidirezionali che coinvolge percorsi neurali e immunoendocrini. Questa complessa interazione influenza profondamente sia il microbiota intestinale che il comportamento del cervello. La disbiosi del patobioma intestinale è rilevante per la patogenesi di disturbi gastrointestinali funzionali, sindromi dolorose croniche, disturbi neurologici e mentali. Di conseguenza, il targeting del microbiota intestina-le sta emergendo come una nuova, efficace prospettiva terapeutica. Tra le molte opzioni di trattamento, gli interventi psicologici, inclusa l’ipnosi, sono stati utilizzati per modulare lo Psicobioma e il suo analogo ipnotico, l’Ipnobioma. Oltre a una revisione della letteratura recente, viene riportato uno studio pilota su una paziente con Sindrome del colon irritabile (IBS) trattata con successo con ipnosi simil-quantica. L’esito positivo del trattamento è stato associato a una significativa di-minuzione di taxa microbici patologici concomitante con un aumento di taxa fi-siologici. Questi risultati preliminari suggeriscono che l’Ipnobioma può rappresentare una nuova promettente frontiera dell’ipnositerapia.;

Keywords:ipnositerapia, asse intestino-cervello, sindrome del colon irritabile, ipnosi simil-quantica, Ipnobioma.

  1. Aarts E., Ederveen T., Naaijen J., Zwiers, M., Boekhorst J., Timmerman H. (2017). Gut microbiome in ADHD and its relation to neural reward anticipation. PLoS One, 12(9): e0183509.
  2. Aroniadis O., Brandt L., Oneto C., Feuerstadt P., Sherman A., Wolkoff A., Kassam Z., Sadovski R., Elliott R., Kim M., Keller M.J. (2019). Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial. Lancet Gastroenterology Hepatology, 4(9): 675-685. DOI: 10.1016/S2468-1253(19)30198-0
  3. Barandouzi Z., Starkweather A., Henderson W., Gyamfi A., Cong X. (2020) Altered Composition of Gut Microbiota in Depression: A Systematic Review. Frontiers in Psychiatry.
  4. Bastiaanssen T., Cowan C., Claesson M., Dinan T., Cryan J. (2019). Making Sense of the Microbiome in Psychiatry. International Journal of Neuropsychopharmacology, 22(1): 37-52.
  5. Bercik P., Collins S. (2014). The effects of inflammation, infection and antibiotics on the microbiota-gut-brain axis. Advances in Experimental Medicine and Biology, 817: 279-289. DOI: 10.1007/978-1-4939-0897-4_13
  6. Berg G., Rybakova D., Fischer D., Cernava T., Vergès M., Charles T., Chen X., Cocolin L., Mauchline T., McClure R., Mitter B., Ryan M., Sarand I., Smidt H., Schelkle B., Roume H., Kiran G., Selvin J., de Souza R., van Overbeek L., Singh B., Wagner M., Walsh A., Sessitsch A., Schloter M. (2020) Microbiome definition re-visited: old concepts and new challenges. Microbiome, 8(103): 1-22. 
  7. Boer C., Radjabzadeh D., Medina-Gomez C., Garmaeva S., Schiphof D., Arp P., Koet T-, Kurilshikov A., Fu J., Ikram M., Bierma-Zeinstra S., Uitterlinden A., Kraaij R., Zhernakova A., van Meurs J. (2019) Intestinal microbiome composition and its relation to joint pain and inflammation. Nature Communications, 10(1): 4881.
  8. Bonaz B., Bazin T., Pellissier S. (2018). The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis. Frontiers Neuroscience, 12: 49
  9. Breit S., Kupferberg A., Rogler G., Hasler G. (2018). Vagus Nerve as Modulator of the Brain–Gut Axis in Psychiatric and inflammatory Disorders. Frontiers Psychiatry, 9: 44.
  10. Cammarota G., Ianiro G., Bibbò S., Gasbarrini A. (2014). Gut microbiota modulation: probiotics, antibiotics or fecal microbiota transplantation? Internal and Emergency Medicine, 9(4): 365-73.
  11. Cowan C., Hoban A., Ventura-Silva P., Cryan J. (2017). Gutsy Moves: The Amygdala as a Critical Node in Microbiota to Brain Signaling. BioEssays, 40(1): 1700-172.
  12. Cryan J., Dinan T. (2012). Mind-altering microorganisms: the impact of the gut microbiota on brain and behavior. Nature Reviews Neuroscience.
  13. De Benedittis G. (2016). Hypnosis and Fibromyalgia, in “Handbook of Medical and Psychological Hypnosis” (Elkins G. Ed.), pp. 235-244, Springer Publishing Company: New York.
  14. De Benedittis G. (2020). From Quantum Physics to Quantum Hypnosis: A Quantum Mind Perspective. International Journal of Clinical and Experimental Hypnosis, 68 (4): 433-450,
  15. De Benedittis G., Cigada M., Bianchi A., Signorini M., Cerutti S. (1994). Autonomic Changes During Hypnosis: A Heart Rate Variability Power Spectrum Analysis as a marker of Sympatho-Vagal Balance. International Journal of Clinical and Experimental Hypnosis, 42 (2): 141-153.
  16. Defaye M., Gervason S., Altier C., Berthon J., Ardid D., Filaire E., Carvalho F. (2020). Neural Microbiota: a novel regulator of pain. Journal Neural Transmission (Vienna), 127(4): 445-465.
  17. Deutsch J., Levitt J., Hass D. (2020). Complementary and Alternative Medicine for Functional Gastrointestinal Disorders. The American Journal of Gastroenterology, 115(3): 350-364
  18. Erdrich S., Hawrelak J., Myers S., Harnett J. (2020). Determining the association between fibromyalgia, the gut microbiome and its biomarkers: A systematic review. BMC Musculoskeletal Disorders, 21: 181.
  19. Evrensel A., Ceylan M. (2016). Fecal Microbiota Transplantation and Its Usage in Neuropsychiatric Disorders. Clinical Psychopharmacology and Neuroscience, 14(3):231-7.
  20. Forsythe P., Kunze W., Bienenstock J. (2016). Moody microbes or fecal phrenology: what do we know about the microbiota-gut-brain axis? BMC Medicine, 14-58.
  21. Foster J., Rinaman L., Cryan J. (2017). Stress and the gut-brain axis: regulation by the microbiome. Neurobiology of Stress, 7: 124-136.
  22. Strati F., Cavalieri D., Albanese D., De Felice C., Donati C., Hayek J. (2017). New evidences on the altered gut microbiota in autism spectrum disorders. Microbiome, 5: 24.
  23. Francis C., Morris J., Whorwell P. (2003). The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Alimentary Pharmacology and Therapeutics, 11(2): 395-402.
  24. Freestone P., Sandrini S., Haigh R., Lyte M. (2008). Microbial endocrinology: how stress influences susceptibility to infection. Trends in Microbiology, 16: 55-64.
  25. Gershon M. (1998). The Second Brain: The Scientific Basis of Gut Instinct and a Groundbreaking New Understanding of Nervous Disorders of the Stomach and the Intestine. HarperCollins.
  26. Gonsalkorale W. (2006). Gut-directed hypnotherapy: The Manchester approach for treatment of irritable bowel syndrome. International Journal of Clinical and Experimental Hypnosis, 54: 27-50. DOI: 10.1080/00207140500323030
  27. Grochowska M., Laskus T., Radkovski M. (2019). Gut Microbiota in Neurological Disorders. Archivum Immunologiae et Therapiae Experimentalis (Warsz). 67(6): 375-383. 
  28. Group N. (2008). Who are we. Nature, 453-563. DOI: 10.1038/453563
  29. Guo R., Chen L-H., Xing C., Liu T. (2019) Pain regulation by gut microbiota: molecular mechanisms and therapeutic potential. British Journal of Anaesthesia, 123(5): 637-654.
  30. Kavvadia M., De Santis G., Alwardat N., Bigioni G., Zeppieri C., Cascapera S., De Lorenzo A. (2017). Psychobiotics As Integrative Therapy for Neuropsychiatric Disorders with Special Emphasis on the Microbiota-Gut-Brain Axis. Biomedicine & Prevention, 2 (111). DOI: 10.19252/00000006F-81-88
  31. Keefer L., Palsson O., Pandolfino J. (2018). Best Practice Update: Incorporating Psychogastroenterology Into Management of Digestive Disorders. Gastroenterology,154(5): 1249-1257.
  32. Keefer L., Taft T., Kiebles J., Martinovich Z., Barrett T., Palsson O. (2013). Gut-directed hypnotherapy significantly augments clinical remission in quiescent ulcerative colitis. Alimentary Pharmacology Therapeutics, 38: 761-771.
  33. Kinsinger S., Ballou S., Keefer L. (2015). Snapshot of an integrated psychosocial gastroenterology service. World Journal of Gastroenterology, 21(6): 1893-1899.
  34. Leclercq S., Forsythe P., Bienenstock J. (2016). Posttraumatic stress disorder: does the gut microbiome hold the key? Canadian Journal of Psychiatry, 61: 204-213. DOI: 10.1177/0706743716635535
  35. Lee Y., Mazmanian S. (2010). Has the microbiota played a critical role in the evolution of the adaptive immune system? Science 330: 1768-1773.
  36. Levy M., Kolodziejczyk A., Thaiss C., Elinav E. (2017). Dysbiosis and the immune system. Nature Reviews Immunology, 17(4): 219-232.
  37. Liang S., Wang T., Hu X., Li W., Jin F., Wang L. (2012). Microorganism and behavior and psychiatric disorders (Article in Chinese). Advances in Methods and Practices in Psychological Science, 20: 75-97. DOI: 10.3724/SP.J.1042.2012.00075
  38. Liang S., Wu X., Jin F. (2018). Gut-Brain Psychology: Rethinking Biology from Microbiota-Gut-Brain Axis. Frontiers Integrative Neuroscience.
  39. Lyte M., Cryan J. (2014). Microbial Endocrinology: The Microbiota-Gut-Brain Axis in Health and Disease. Springer.
  40. Lyte M., Freestone P. (2010). Microbial Endocrinology: Interkingdom Signaling in Infectious Disease and Health. New York, NY: Springer. 
  41. Manrique P., Dills M., Young M. (2017). The human gut phage community and its implications for health and disease. Viruses, 9.
  42. Margulis L., Fester R. (1991). Symbiosis as a Source of Evolutionary Innovation. MIT Press. 
  43. Marizzoni M., Cattaneo A., Mirabelli P., Festari C., Lopizzo N., Nicolosi V., Frisoni G. (2020). Short-Chain Fatty Acids and Lipopolysaccharide as Mediators Between Gut Dysbiosis and Amyloid Pathology in Alzheimer’s Disease. Journal Alzheimers Disease, 78(2): 683-697. DOI: 10.3233/JAD-200306
  44. Matarazzo I., Toniato E., Robuffo I. (2018). Psychobiome Feeding Mind: Polyphenolics in Depression and Anxiety. Current Topics in Medicinal Chemistry, 18(24): 2108-2115. DOI: 10.2174/1568026619666181210151348
  45. Mazzoli R., Passione E. (2016). The Neuro-endocrinological Role of Microbial Glutamate and GABA Signaling. Frontiers Microbiology, 7: 1934. 
  46. Menes S., Chey W. (2018). The gut microbiome and irritable bowel syndrome. F1000Research.
  47. Minerbi A., Gonzalez E., Brereton N., Anjarkouchian A., Dewar K., Fitzcharles M., Chevalier S., Shir Y. (2019). Altered microbiome composition in individuals with fibromyalgia. Pain, 160(11): 2589-2602.
  48. Moloney R., Johnson A., O’Mahony S., Dinan T., Greenwood-Van Meerveld, B., Cryan J. (2016). Stress and the Microbiota–Gut–Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome. CNS Neuroscience & Therapeutics, 22(2): 102-117.
  49. Moser G., Trägner S., Gajowniczek E., Mikulits A., Michalski M., Kazemi-Shirazi L., Kulnigg-Dabsch S., Führer M., Ponocny-Seliger E., Dejaco C. (2013). Long-term success of GUT-directed group hypnosis for patients with refractory irritable bowel syndrome: A randomized controlled trial. American Journal of Gastroenterology, 108: 602-609.
  50. Neuman H., Debelius J., Knight R., Koren O. (2015). Microbial endocrinology: the interplay between the microbiota and the endocrine system. FEMS Microbiology Reviews. 39: 509-521.
  51. O’Mahony S., Clarke G., Borre Y., Dinan T., Cryan J. (2014). Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behavioral Brain Research, 277: 32-48.
  52. Palsson O., Turner M., Johnson D., Burnett C., Whitehead W. (2002). Hypnosis treatment for severe irritable bowel syndrome: Investigation of mechanism and effects on symptoms. Digestive Diseases and Sciences, 47: 2605-2614. DOI: 10.1023/A:1020545017390.
  53. Pennisi E. (2016). Microbiome. Science, 19: 351-802.
  54. Peter J., Fournier C., Keip B., Rittershaus N., Stephanou-Rieser N., Durdevic M., Dajaco C., Michalski M., Moser G. (2018). Intestinal Microbiome in Irritable Bowel Syndrome before and after Gut-Directed Hypnotherapy. International Journal of Molecular Sciences,19(11): 3619. 
  55. Pusceddu M., Gareau M. (2017). Visceral pain: gut microbiota, a new hope? Journal of Biomedical Science, 25(1): 73.
  56. Quigley E. (2017). Microbiota-brain-gut axis and neurodegenerative diseases. Current Neurology and Neuroscience Reports, 17: 94.
  57. Rodiño-Janeiro B., Vicaria M., Alonso-Cotoner C., Pascua-Garcia R., Santos J. (2018). A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies. Advances in Therapy, 35(3): 289-310.
  58. Rutten J., Korterink J., Venmans L., Benninga M., Tabbers M. (2015). Nonpharmacologic treatment of functional abdominal pain disorders: a systematic review. Pediatrics, 135(3): 522-35.
  59. Schnorr S., Bachner H. (2016). Integrative therapies in anxiety treatment with special emphasis on the gut microbiome. Yale Journal of Biology and Medicine., 89: 397-422.
  60. Simrén M., Ringström G., Björnsson E., Abrahamsson H. (2004). Treatment with hypnotherapy reduces the sensory and motor component of the gastrocolonic response in irritable bowel syndrome. Psychosomatic Medicine, 66: 233-238.
  61. Tap J., Derrien M., Törnblom H., Brazeilles R., Cools-Portier ,S., Doré J., Dimrèn M. (2017). Identification of an Intestinal Microbiota Signature Associated with Severity of Irritable Bowel Syndrome. Gastroenterology,152(1): 111-123.
  62. Thakur E., Shapiro J., Chan J., Lumley M., Cully J., Bradford A., El-Serag H.B. (2018). A Systematic Review of the Effectiveness of Psychological Treatments for IBS in Gastroenterology Settings: Promising but in Need of Further Study. Digestive Diseases and Sciences, 63(9): 2189-2201.
  63. Tlaskovà-Hogenovà H., Stepankova R., Kozakova H., Hudcovic T., Vannucci L., Tuckova L., Rossmann P., Hrncir T., Kverka M., Zakostelska Z., Klimesova K., Pribilova J., Bartova J., Sanchez D., Fundova P., Borovska D., Srutkova D., Zidek Z., Schwarzer D., Drastich P., Funda D.P., Borovska D., Srutkova D., Zidek Z., Schwarzer M., Drastich P., Funda D.P. (2011).The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cellular & Molecular Immunology, 8(2): 110-20.
  64. Turna J., Grosman Kaplan K., Anglin R., Van Ameringen M. (2016). “What’s bugging the gut in Ocd?” a review of the gut microbiome in obsessive-compulsive disorder. Depression and Anxiety, 33: 171-178. 
  65. Turnbaugh P., Ley R., Hamady M., Fraser-Liggett C., Knight, R., Gordon J. (2007). The Human Microbiome Project. Nature, 449: 804-810.
  66. Valles-Colomer M., Falony G., Darzi Y., Tigchelaar E.F., Wang J., Tito R.Y., Schiweck C., Kurilshikov A., Joossens M., Wijmenga C., Claes S., Van Oudenhove L., Zhernakova A., Vieira-Silva S., Raes J. (2019). The neuroactive potential of the human gut microbiota in quality of life and depression. Nature Microbiology, 4(4): 623-632.
  67. Wang B., Yao M., Lv L., Ling Z., LiL. (2017). The Human Microbiota in Health and Disease. Engineering, 3(1): 71-82. DOI: 10.1016/J.ENG.2017.01.008
  68. Whorwell P. (2008). Hypnotherapy for irritable bowel syndrome: The response of colonic and noncolonic symptoms. Journal of Psychosomatic Research, 64: 621-623.
  69. Whorwell P., Prior A., Faragher E. (1984). Controlled trial of hypnotherapy in the treatment of severe irritable bowel syndrome. Lancet, 324: 1232-1234. DOI: 10.1016/S0140-6736(84)92793-4
  70. Wood J. (2007). Neuropathophysiology of functional gastrointestinal disorders. World Journal of Gastroenterology, 13: 1313-1332.
  71. Yano J., Yu K., Donaldson G., Shastri G., Ann P., Ma L., Nagler C., Ismagilov R., Mazmanian S., Hsiao E. (2015). Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell, 161(2): 264-76.
  72. Zhao L., Xiong W., Stary C., Mahgoub O., Ye Y., Gu L., Xiong X., Zhu S. (2018). Bidirectional gut-brain-microbiota axis as a potential link between inflammatory bowel disease and ischemic stroke. Journal of Neuroinflammation, 15: 339.
  73. Woolf S. (2008). The meaning of translational research and why it matters. Jama, 299(2): 211-213.

Giuseppe De Benedittis, Ipnobioma: una nuova frontiera dell’ipnositerapia? Uno studio pilota e una revisione della letteratura in "IPNOSI" 2/2021, pp 5-25, DOI: 10.3280/IPN2021-002001